Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Xi's position as the apparent successor to become the paramount leader was threatened with the rapid rise of Bo Xilai, the party secretary of Chongqing at the time. Bo was expected to join the PSC after the 18th Party Congress, with most expecting that he would try to eventually maneuver himself into replacing Xi. Bo's policies in Chongqing inspired imitations throughout China and received praise from Xi himself during Xi's visit to Chongqing in 2010. Records of praises from Xi were later erased after he became paramount leader. Bo's downfall would come with the Wang Lijun incident, which opened the door for Xi to come to power without challengers. On 18 October 2010, at the fifth plenary session of the 17th Central Committee, Xi was elected to be a vice chairman of the CCP Central Military Commission, followed by his appointment as vice chairman of the state CMC on 28 October by the Standing Committee of the National People's Congress. A few months before his ascendancy to the party leadership, Xi disappeared from official media coverage and cancelled meetings with foreign officials for several weeks beginning on 1 September 2012, causing rumors. He then reappeared on 15 September. On 15 November 2012, immediately after the 18th Party National Congress, Xi was elected by the first plenary session the 18th Central Committee to the posts of Party general secretary and chairman of the Party CMC. This made him both the CCP leader and, informally, China's paramount leader. The following day Xi led the new line-up of the PSC onto the stage in their first public appearance.
on the toxicity findings of publicly-funded academics, whose methods are very heterogeneous, but who test, and often find, toxicity at much lower doses that industry's TG studies); or, a nation may interpret the accepted study's results according to its own criteria. According to OECD Council Decision C(97)186/Final, chemical testing data generated in any OECD member country following OECD Test Guidelines and GLP principles is recognized by other OECD member countries, such as Australia, Canada, Korea, and the USA. This recognition also extends to some non-OECD countries that fully adhere to the mutual acceptance of data (MAD) under OECD Council Decision C(97)114/Final, including Brazil, India, Malaysia, Singapore, and South Africa, as well as Argentina for industrial chemicals, pesticides, and biocides only. In June 2004, the US FDA published a comparison chart of FDA and EPA Good Laboratory Practice (GLP) regulations alongside OECD Principles for GLP, aiding in understanding the key differences and similarities in GLP standards across these regulatory bodies. Note, unlike many countries, the US EPA names its mandated use of the OECD TG, ‘the EPA Test Methods’.
=== Pharmacokinetics === Pindolol is rapidly and well-absorbed from the gastrointestinal tract. It undergoes some first-pass metabolism leading to an oral bioavailability of 50 to 95%. Patients with uremia may have a reduced bioavailability. Food does not alter the bioavailability, but may increase the resorption. Following an oral single dose of 20 mg peak plasma concentrations are reached within 1 to 2 hours. The effect of pindolol on pulse rate (lowering) is evident after 3 hours. The drug's volume of distribution is 1.2 to 2 L/kg. The plasma protein binding is 40 to 60%. It crosses the blood–brain barrier and can produce centrally mediated side effects. Despite being moderately lipophilic, pindolol showed greater electroencephalogram (EEG) changes than the highly lipophilic propranolol. As a result, lipophilicity does not appear to be the sole determinant of blood–brain barrier permeability of beta blockers. Approximately two-thirds of pindolol is metabolized in the liver giving hydroxylates, which are found in the urine as gluconurides and ethereal sulfates. The remaining one-third of pindolol is excreted in urine in unchanged form. Despite the rather short elimination half-life of 3 to 4 hours, hemodynamic effects persist for 24 hours after administration. The half-life is increased to 3 to 11.5 hours in patients with renal impairment, to 7 to 15 hours in elderly patients, and from 2.5 to 30 hours in patients with liver cirrhosis.
Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. It was developed by Onyx Pharmaceuticals. The US Food and Drug Administration (FDA) approved it in July 2012.
The Defense Secretary threatened Anthropic, the owner of Claude AI (the only AI authorized by the Department of Defense in early 2026), to designate the company a supply chain risk and force the company to eliminate its restrictions on the use of its AI by the Defense Department or he will use the Defense Production Act to compel them. The Defense Department gave Anthropic a deadline of February 27, 2026. The contract Sec. Hegseth wanted to cancel was worth $200 million. A senior defense official stated that the company will "pay a price for forcing our hand like this." Anthropic stated that they wanted assurances that the DoD would not use their AI tools to spy on Americans or develop weapons that could fire without human involvement. The Defense Department also stated in February 2026 that Grok, OpenAI and Google were close to being approved for use. Claude was used by the Pentagon during their January 2026 operation to capture Nicolas Maduro. In May 2026, the Defense Department announced AI use deals with SpaceX, OpenAI, Google, NVIDIA, Reflection, Microsoft and Amazon Web Services. On February 27, 2026, Hegseth used the Federal Acquisition Supply Chain Security Act to declare Anthropic a supply chain risk and excluded it from all federal contracts. President Trump also stated that every federal agency must stop using Anthropic's AI technology. ChatGPT signed a deal with the Defense Department the same day but their CEO Sam Altman said, "the AI system shall not be intentionally used for domestic surveillance of U.S.
Sources: en.wikipedia.org
James H. Gilliam, Jr. College of Liberal Arts School of Computer, Mathematical, and Natural Sciences Clarence M. Mitchell School of Engineering School of Architecture and Planning Earl G. Graves School of Business and Management School of Community Health and Policy School of Global Journalism and Communication School of Education & Urban Studies School of Social Work College of Interdisciplinary and Continuing Studies Dr. Clara Adams Honors College School of Graduate Studies Patuxent Environmental & Aquatic Research Laboratory (PEARL)
== Legal status == Difenoxin is a Schedule I drug by itself in the US; the combination with atropine is in the less-restrictive category Schedule IV on account of the adulterant (the practice of making opioids more easily available by including an abuse-deterring adulterating agent is standard practice in the United States). Pure difenoxin, in Schedule I, has a quota of 50 grammes, and an ACSCN of 9168. The combination of difenoxin and atropine, in Schedule IV, has the DEA ACSCN of 9167 and being in Schedule IV is not assigned an aggregate annual manufacturing quota.
== Organisation == NCCD is overseen by a Governing Council and an Executive Committee, with equal representation of public and private sectors, chaired by the Secretary (A&C, Ministry of Agriculture). The principal executive of this body was originally conceived as its Director who would implement the decisions of the Executive Body. The first Director of NCCD was Mr. Sanjeev Chopra, a Joint Secretary in the Ministry of Agriculture. However, in keeping with the technical domain requirements, the governing bodies initially decided to invite an established leader from the private sector as a chief advisor to assist in incubating the body and develop a roadmap. In this initial stage, various concept level revisions were proposed regarding cold chain and the requirements to make it future ready. In these years, India's horticultural production also overtook that in food grains. Subsequently, in 2014 the Governing Council decided that this body required to be strengthened with relevant domain expertise. It restructured the organization and added the position of Chief Executive Officer, to be filled by an industry stalwart with hands-on domain experience. The government officer nominated Director, was thereafter to provide administration support, with the professional Chief Executive Officer responsible to provide executive and technical direction. Capt. Pawanexh Kohli was the first Chief Advisor and the founding Chief Executive Officer of NCCD and headed this organization for its first eight years from 2012 to 2020.
=== Driving forces for moisture movement === Three main driving forces used in different version of diffusion models are moisture content, the partial pressure of water vapour, and the chemical potential of water. These are discussed here, including capillary action, which is a mechanism for free water transport in permeable softwoods. Total pressure difference is the driving force during wood vacuum drying.
Sources: en.wikipedia.org
Unlike many other hormones, adrenaline (as with other catecholamines) does not exert negative feedback to down-regulate its own synthesis. Abnormal adrenaline levels can occur in various conditions, such as surreptitious adrenaline administration, pheochromocytoma, and other tumors of the sympathetic ganglia. Its action is terminated with reuptake into nerve terminal endings, some minute dilution, and metabolism by monoamine oxidase and catechol-O-methyl transferase into 3,4-Dihydroxymandelic acid and Metanephrine.
The IdMOC plate consists of multiple inner wells within a large interconnecting chamber. Multiple cell types are first individually seeded in the inner wells and, when required, are flooded with an overlying medium to facilitate well-to-well communication. Test material can be added to the overlying medium and both media and cells can be analyzed individually. Plating of hepatocytes with other organ-specific cells allows evaluation of drug metabolism and organotoxicity. The IdMOC system has numerous applications in drug development, such as the evaluation of drug metabolism and toxicity. It can simultaneously evaluate the toxic potential of a drug on cells from multiple organs and evaluate drug stability, distribution, metabolite formation, and efficacy. By modeling multiple-organ interactions, IdMOC can examine the pharmacological effects of a drug and its metabolites on target and off-target organs as well as evaluate drug-drug interactions by measuring cytochrome P450 (CYP) induction or inhibition in hepatocytes. IdMOC can also be used for routine and high throughput screening of drugs with desirable ADME or ADME-Tox properties. In vitro toxicity screening using hepatocytes in conjunction with other primary cells such as cardiomyocytes (cardiotoxicity model), kidney proximal tubule epithelial cells (nephrotoxicity model), astrocytes (neurotoxicity model), endothelial cells (vascular toxicity model), and airway epithelial cells (pulmonary toxicity model) is invaluable to the drug design and discovery process. The IdMOC was patented by Dr. Albert P. Li in 2004.
==== Sample preparation ==== In both conventional and in-situ dating, a thin section of the rock of interest is prepared. First, a thin layer of rock is cut by a diamond saw and ground to become optically flat. Then, it is mounted on a slide made of glass or resin, and ground smooth using abrasive grit. The final sample is usually only 30 μm thick.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.